title: Mirtazapine associated with profound hyponatremia: two case reports.
abstract: BACKGROUND
  Depression is a common problem in the elderly, and the recognition and appropriate management of this illness are important aspects of geriatric medicine. Selective serotonin reuptake inhibitors have been associated with hyponatremia, but the association of mirtazapine with hyponatremia is less well documented.
  
  
  OBJECTIVE
  The goal of this research was to highlight and characterize the association between mirtazapine and hyponatremia. We present here 2 case reports as well as the results of a literature review.
  
  
  METHODS
  Two patients, a 61-year-old man and a 79-year-old woman, developed profound hyponatremia (sodium levels, 112 and 113 mEq/L, respectively) 7 and 10 days after commencement of mirtazapine for symptoms of depression. Investigations excluded other causes, and cessation of mirtazapine was associated with recovery of sodium levels to > or =132 mEq/L after 7 and 10 days, respectively.
  
  
  CONCLUSIONS
  The likelihood of mirtazapine use causing hyponatremia in these 2 cases was "probable" according to criteria of the Naranjo Adverse Drug Reaction Probability Scale (score, 6). A review of published cases found that mirtazapine-associated hyponatremia occurred in patients aged >60 years, after a mean of 6.5 days and with doses as low as 7.5 mg daily. The mean sodium nadir was 117.2 mEq/L, but after stopping mirtazapine, the mean time to recovery was 11 days. Clinicians should be aware of the possibility of this reaction in elderly patients and should monitor sodium levels in high-risk patients if symptoms suggestive of hyponatremia develop.
authors.affiliation: Department of General Medicine, Fremantle Hospital and Health Service, Fremantle, Western Australia. ccheah@iinet.net.au
authors.forename: Chan Y
authors.initials: CY
authors.lastname: Cheah
authors.forename: Bronwyn
authors.initials: B
authors.lastname: Ladhams
authors.forename: P Gerry
authors.initials: PG
authors.lastname: Fegan
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D011336:Probability
chemical_list: D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D000078785:Mirtazapine